[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital of Wannan Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":658},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,51,90,109,138,160,190,217,239,264,292,314,340,361,385,408,440,462,489,517,538,558,583,611,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100638514","eit-evaluation-of-different-antihypertensive-agents-on-the-ventilation-perfusion-ratio-in-patients-with-acute-respiratory-failure-100638514",false,"NCT07603037","EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure","Effect of Nicardipine and Nitroglycerin on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure Using Electrical Impedance Tomography: A Prospective Pilot Study","Inclusion Criteria Diagnosis of acute respiratory failure with PaO₂\u002FFiO₂ ≤ 300 mmHg, requiring invasive mechanical ventilation.\n\nRequires intravenous antihypertensive infusion (such as nicardipine or nitroglycerin) to maintain controlled and stable blood pressure during ICU treatment.\n\nWritten informed consent obtained from the patient or the legally authorized representative.\n\nExclusion Criteria:\n\nBody mass index (BMI) ≥ 50 kg\u002Fm² or presence of massive subcutaneous edema interfering with EIT signal acquisition.\n\nImplanted cardiac pacemaker, defibrillator, or any metallic thoracic device that may distort impedance measurements.\n\nHemodynamic instability or severe hypotension occurring during drug titration. Pregnancy or lactation. Known hypersensitivity or contraindication to nicardipine or nitroglycerin. Use of phosphodiesterase-5 inhibitors, such as sildenafil, tadalafil, or vardenafil, within the clinically relevant washout period.\n\nSevere anemia, markedly increased intracranial pressure, or other clinical conditions in which nitroglycerin administration is considered inappropriate by the treating physician.\n\nIncomplete clinical documentation preventing accurate evaluation of primary endpoints.","ALL","18 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, single-center interventional study aims to evaluate the effect of two commonly used intravenous antihypertensive agents - nicardipine and nitroglycerin - on lung ventilation-perfusion (V\u002FQ) distribution in patients with acute respiratory failure complicated by hypertension. Electrical Impedance Tomography (EIT) will be used for noninvasive monitoring of pulmonary ventilation and perfusion distribution before and after drug administration.\n\nThe study will compare the changes in V\u002FQ ratio, oxygenation index, and hemodynamic variables after administration of the two drugs. The findings are expected to provide evidence for the optimal antihypertensive strategy in critically ill patients with respiratory failure and to clarify whether specific vasodilators exacerbate or improve ventilation-perfusion mismatch.",[27,28,29,30],"Acute Respiratory Failure (ARF)","Hypertension","Pulmonary Perfusion Imbalance","Aortic Dissection (Subset)",[32,33,34,35,36,37],"Electrical Impedance Tomography","Ventilation-Perfusion Ratio","Nicardipine","Acute Respiratory Failure","Intensive Care Unit","Nitroglycerin","NOT_YET_RECRUITING","2026-06-30",{"date":41,"type":42},"2026-07-02","ACTUAL",{"date":44,"type":21},"2026-07-15",{"date":46,"type":21},"2027-07-30",{"name":48,"class":49},"First Affiliated Hospital of Wannan Medical College","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":50},"100641107","effects-of-anisodamine-on-sublingual-microcirculation-and-vascular-waterfall-phenomenon-in-patients-with-septic-shock-100641107","NCT07657702","Effects of Anisodamine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock","Effects of Anisodamine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock: A Prospective, Multicenter, Single-arm, Open-label, Pilot Physiological Study","ANISO-MICRO","Inclusion Criteria:\n\n* Age 18-85 years.\n* Diagnosis of septic shock according to Sepsis-3 criteria, defined as suspected or documented infection with vasopressor requirement to maintain mean arterial pressure ≥65 mmHg and serum lactate \\>2 mmol\u002FL after adequate fluid resuscitation.\n* Enrollment within 24 hours after diagnosis of septic shock or within 24 hours after ICU admission for septic shock.\n* Receiving invasive mechanical ventilation at the time of enrollment.\n* PiCCO catheter in place and PiCCO-based hemodynamic monitoring available before anisodamine initiation.\n* Continuous norepinephrine infusion at enrollment.\n* Adequate initial fluid resuscitation and hemodynamic optimization as judged by the treating physician, with volume status assessed by dynamic indices, echocardiography, or PiCCO-derived variables.\n* Ability to obtain sublingual microcirculatory images of acceptable quality at baseline.\n* Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Shock mainly caused by non-septic etiologies, including cardiogenic, hypovolemic, obstructive, hemorrhagic, or anaphylactic shock.\n* Expected death or withdrawal of life-sustaining treatment within 24 hours.\n* Known contraindications to anisodamine or anticholinergic therapy, including glaucoma, acute phase of intracranial hemorrhage, elevated intracranial pressure, untreated bowel obstruction, or prostatic enlargement without urinary catheterization.\n* Known allergy or hypersensitivity to anisodamine or any component of the study drug.\n* Severe or uncontrolled arrhythmia before enrollment, including sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, uncontrolled supraventricular tachycardia, or atrial fibrillation\u002Fflutter with uncontrolled ventricular response.\n* Acute coronary syndrome, clinically significant myocardial ischemia, or cardiac arrest before enrollment during the current ICU stay.\n* Severe cardiac dysfunction judged unsuitable for anisodamine by the treating physician, including severe ventricular dysfunction, cardiogenic shock, or need for high-dose inotropic support.\n* Conditions interfering with sublingual microcirculatory assessment, including major oral or sublingual lesions, active oral bleeding, inability to access the sublingual area, or poor baseline image quality.\n* Immunocompromised status or agranulocytosis, including long-term immunosuppressive therapy, chemotherapy-associated severe neutropenia, or other severe immune suppression judged by the investigator.\n* Pregnancy, planned pregnancy, or lactation.\n* Participation in another interventional clinical trial that may affect study outcomes or safety.\n* Inability to obtain informed consent.","85 Years",{"count":61,"type":21},20,[24],"This prospective, multicenter, single-arm, open-label interventional pilot study aims to evaluate the short-term physiological effects of intravenous anisodamine on sublingual microcirculation and vascular-waterfall parameters in adult patients with septic shock.\n\nEligible patients will have septic shock according to Sepsis-3 criteria, will require norepinephrine support after adequate fluid resuscitation, and will be receiving invasive mechanical ventilation and PiCCO-based hemodynamic monitoring. After baseline assessment, participants will receive intravenous anisodamine according to the study protocol. Anisodamine will be administered as a loading dose of 0.5 mg\u002Fkg within 3 minutes, with a minimum dose of 20 mg and a maximum dose of 40 mg, followed by continuous infusion at 0.02-0.1 mg\u002Fkg\u002Fhour, with a maximum total daily dose of 200 mg.\n\nSublingual microcirculatory variables, including microvascular flow index, perfused vessel density, proportion of perfused vessels, and heterogeneity index, as well as vascular-waterfall parameters, including estimated critical closing pressure, estimated mean systemic filling pressure, and the Pcc-Pmsf gradient, will be measured at baseline, 3 hours, and 6 hours after initiation of anisodamine. Systemic hemodynamic, perfusion, vasopressor, PiCCO-derived variables, and safety outcomes will also be collected.\n\nThe primary objective is to characterize immediate changes in sublingual microcirculation and vascular-waterfall physiology after anisodamine administration and to provide preliminary data for future controlled studies.",[65,66,67],"Septic Shock","Sepsis","Critical Illness",[69,70,71,72,73,74,75,76,77,78,79,80,81],"anisodamine","anisodamine hydrobromide","septic shock","sublingual microcirculation","microvascular flow index","vascular waterfall","critical closing pressure","mean systemic filling pressure","Pcc","Pmsf","PiCCO","mechanical ventilation","arrhythmia","2026-06-14",{"date":84,"type":42},"2026-06-18",{"date":86,"type":21},"2026-08-01",{"date":88,"type":21},"2027-12-30",{"name":48,"class":49},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":107,"locationsCount":108},"100641364","effects-of-esmolol-on-sublingual-microcirculation-and-vascular-waterfall-phenomenon-in-patients-with-septic-shock-100641364","NCT07657754","Effects of Esmolol on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock","Effects of Esmolol on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock: A Prospective, Multicenter, Single-arm, Open-label, Pilot Physiological Study","Inclusion Criteria:\n\nAge 18-85 years. Diagnosis of septic shock according to Sepsis-3 criteria, requiring norepinephrine to maintain MAP ≥65 mmHg after adequate fluid resuscitation.\n\nPersistent tachycardia after initial hemodynamic optimization, adequate analgesia\u002Fsedation, and correction of reversible causes, defined as heart rate ≥95 beats\u002Fmin.\n\nContinuous norepinephrine infusion for ≥6 hours, with norepinephrine dose ≥0.10 μg\u002Fkg\u002Fmin at enrollment.\n\nAdequate volume status or absence of fluid responsiveness assessed by dynamic indices, echocardiography, or advanced hemodynamic monitoring; if PiCCO is used, GEDVI \\>700 mL\u002Fm² and\u002For ITBVI \\>850 mL\u002Fm² may be used as supportive criteria.\n\nPreserved or hyperdynamic cardiac function before esmolol initiation, defined as cardiac index \\>3.0 L\u002Fmin\u002Fm² or absence of severe septic cardiomyopathy.\n\nAbility to obtain sublingual microcirculatory images of acceptable quality at baseline.\n\nWritten informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\nShock mainly caused by non-septic etiologies, including cardiogenic, hypovolemic, obstructive, hemorrhagic, or anaphylactic shock.\n\nSevere cardiac dysfunction or severe septic cardiomyopathy, including cardiac index \\\u003C2.2 L\u002Fmin\u002Fm² despite adequate preload, severe ventricular dysfunction, or need for inotropic agents at enrollment.\n\nUse of β-blockers before ICU admission or within 24 hours before enrollment. Contraindications to esmolol or β-blockade, including high-grade atrioventricular block without pacing, severe bradycardia, sick sinus syndrome, severe bronchospasm\u002Fasthma, or known allergy to esmolol.\n\nSevere structural heart disease or major pulmonary conditions affecting hemodynamics or safety, including severe valvular disease, significant congenital heart disease, cardiomyopathy, severe pulmonary bullae, or untreated pneumothorax.\n\nAcute coronary syndrome, life-threatening arrhythmia, or cardiac arrest before enrollment during the current ICU stay.\n\nConditions interfering with sublingual microcirculatory assessment, including major oral\u002Fsublingual lesions, active oral bleeding, inability to access the sublingual area, or poor baseline image quality.\n\nPregnancy or lactation, expected death or withdrawal of life-sustaining treatment within 24 hours, expected ICU stay \\\u003C48 hours, or inability to obtain informed consent.",{"count":61,"type":21},[24],"This prospective, multicenter, single-arm interventional pilot study aims to evaluate the short-term physiological effects of intravenous esmolol on sublingual microcirculation and vascular-waterfall parameters in adult patients with septic shock. Eligible patients will have septic shock according to Sepsis-3 criteria, persistent tachycardia after initial hemodynamic optimization, ongoing norepinephrine support, adequate volume status or absence of significant fluid responsiveness, and preserved or hyperdynamic cardiac function.\n\nApproximately 20 patients will be enrolled from participating intensive care units. After baseline assessment, participants will receive continuous intravenous esmolol infusion according to the study protocol and clinical safety criteria. Sublingual microcirculatory variables, including microvascular flow index, perfused vessel density, proportion of perfused vessels, and heterogeneity index, as well as vascular-waterfall parameters, including estimated critical closing pressure, estimated mean systemic filling pressure, and the Pcc-Pmsf gradient, will be measured at baseline and at 3, and 6 hours after esmolol initiation. Additional systemic hemodynamic, perfusion, vasopressor, and safety variables will also be collected.\n\nThe primary objective is to characterize immediate changes in sublingual microcirculation and vascular-waterfall physiology after esmolol administration and to provide preliminary data for the design of future controlled studies.",[65,66,101],"Critical Illness Sepsis, Severe",[103,72,73,75,76,74,65],"esmolol",{"date":84,"type":42},{"date":86,"type":21},{"date":88,"type":21},{"name":48,"class":49},2,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":134,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":137,"locationsCount":108},"100641345","papaverine-and-sublingual-microcirculation-in-septic-shock-100641345","NCT07657741","Papaverine and Sublingual Microcirculation in Septic Shock","Effects of Papaverine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock: A Prospective, Multicenter, Single-arm, Open-label, Pilot Physiological Study","Inclusion Criteria:\n\n* Age 18-85 years.\n* Septic shock according to Sepsis-3 criteria, defined as suspected or documented infection requiring vasopressors to maintain mean arterial pressure ≥65 mmHg and serum lactate \\>2 mmol\u002FL after adequate fluid resuscitation.\n* Enrollment within 24 hours after diagnosis of septic shock in the ICU.\n* Receiving continuous norepinephrine infusion at enrollment.\n* Receiving invasive mechanical ventilation at enrollment, allowing assessment of vascular waterfall-related hemodynamic variables.\n* PiCCO-based hemodynamic monitoring, invasive arterial pressure monitoring, and central venous access available before papaverine administration.\n* Ability to obtain sublingual microcirculatory images of acceptable quality at baseline.\n* Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Shock primarily caused by non-septic etiologies, including cardiogenic, hypovolemic, obstructive, hemorrhagic, or anaphylactic shock.\n* Expected death or planned withdrawal of life-sustaining treatment within 24 hours.\n* Known allergy or hypersensitivity to papaverine.\n* Severe hemodynamic instability judged unsuitable for papaverine by the treating physician, including refractory hypotension or rapidly escalating vasopressor requirement.\n* Clinically significant arrhythmia, high-grade atrioventricular block, acute coronary syndrome, or active myocardial ischemia before enrollment.\n* Severe hepatic dysfunction judged by the investigator to substantially increase the risk of papaverine-related adverse effects.\n* Conditions preventing reliable sublingual microcirculatory assessment, including major oral or sublingual lesions, active oral bleeding, inability to access the sublingual area, or poor baseline image quality.\n* Pregnancy or lactation.\n* Participation in another interventional clinical trial that may affect study outcomes or safety.",{"count":61,"type":21},[24],"This is a prospective, multicenter, single-arm, open-label, pilot physiological study designed to evaluate the effects of intravenous papaverine on sublingual microcirculation and the vascular waterfall phenomenon in adult patients with septic shock.\n\nEligible patients will have septic shock according to Sepsis-3 criteria, require norepinephrine support after adequate fluid resuscitation, and have PiCCO-based hemodynamic monitoring available before papaverine administration. Papaverine will be administered as an intravenous infusion of 30 mg over 10 minutes, followed by a continuous infusion of 2-5 mg\u002Fhour. Sublingual microcirculatory variables, vascular-waterfall-related indices, PiCCO-derived hemodynamic variables, macrocirculatory parameters, tissue perfusion variables, vasopressor dose, and safety outcomes will be assessed before and after papaverine administration.\n\nThe study aims to explore whether papaverine can improve microvascular perfusion and reduce microcirculatory flow impairment in septic shock, and to provide preliminary physiological and safety data for future controlled trials.",[65,120,121,122],"Microcirculatory Dysfunction","Sublingual Microcirculation","Hemodynamic Instability",[124,125,126,127,128,129,130,131,132,133],"Septic shock","Papaverine","Sublingual microcirculation","Microcirculatory dysfunction","Vascular waterfall phenomenon","Critical closing pressure","Perfused vessel density","Microvascular flow index","Proportion of perfused vessels","Pilot physiological study",{"date":84,"type":42},{"date":86,"type":21},{"date":88,"type":21},{"name":48,"class":49},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":159,"locationsCount":108},"100641303","effects-of-dexmedetomidine-on-sublingual-microcirculation-and-vascular-waterfall-phenomenon-in-patients-with-septic-shock-100641303","NCT07657715","Effects of Dexmedetomidine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock","Effects of Dexmedetomidine on Sublingual Microcirculation and Vascular Waterfall Phenomenon in Patients With Septic Shock: A Prospective, Multicenter, Single-arm, Open-label, Pilot Physiological Study","DEX-MICRO","Inclusion Criteria:\n\n* Age 18-85 years.\n* Diagnosis of septic shock according to Sepsis-3 criteria, defined as suspected or documented infection with vasopressor requirement to maintain mean arterial pressure ≥65 mmHg and serum lactate \\>2 mmol\u002FL after adequate fluid resuscitation.\n* Enrollment within 24 hours after diagnosis of septic shock in the ICU.\n* Receiving invasive mechanical ventilation.\n* Receiving continuous intravenous sedative and\u002For analgesic therapy other than dexmedetomidine before enrollment, with a clinical decision to add dexmedetomidine for sedation management.\n* Continuous norepinephrine infusion at enrollment.\n* PiCCO catheter in place and PiCCO-based hemodynamic monitoring available before dexmedetomidine initiation.\n* Written informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria:\n\n* Shock primarily caused by non-septic etiologies, including cardiogenic, hypovolemic, obstructive, hemorrhagic, or anaphylactic shock.\n* Expected death or withdrawal of life-sustaining treatment within 24 hours.\n* Known allergy or hypersensitivity to dexmedetomidine.\n* Severe bradycardia or clinically significant conduction abnormality before enrollment, including heart rate \\\u003C50 beats\u002Fmin, second-degree or third-degree atrioventricular block, sick sinus syndrome, or other conduction abnormality without a functioning pacemaker.\n* Severe uncontrolled arrhythmia, acute coronary syndrome, or clinically significant myocardial ischemia before enrollment.\n* Severe hemodynamic instability judged unsuitable for dexmedetomidine by the treating physician, including refractory hypotension or rapidly escalating vasopressor requirement.\n* Severe hepatic dysfunction judged by the investigator to substantially increase the risk of dexmedetomidine accumulation or adverse effects.\n* Conditions interfering with sublingual microcirculatory assessment, including major oral or sublingual lesions, active oral bleeding, inability to access the sublingual area, or poor baseline image quality.\n* Pregnancy or lactation.\n* Participation in another interventional clinical trial that may affect study outcomes or safety.",{"count":61,"type":21},[24],"This prospective, multicenter, single-arm, open-label interventional pilot study aims to evaluate the short-term physiological effects of intravenous dexmedetomidine on sublingual microcirculation and vascular-waterfall parameters in adult patients with septic shock.\n\nEligible patients will have septic shock according to Sepsis-3 criteria, require norepinephrine support after adequate fluid resuscitation, receive invasive mechanical ventilation, and have PiCCO-based hemodynamic monitoring available before dexmedetomidine initiation. After baseline assessment, participants will receive intravenous dexmedetomidine according to the study protocol. Dexmedetomidine will be administered as a continuous intravenous infusion at 0.2-0.7 µg\u002Fkg\u002Fhour without a loading dose. The infusion rate may be adjusted according to the target sedation level, hemodynamic status, and adverse effects.\n\nSublingual microcirculatory variables, including microvascular flow index, perfused vessel density, proportion of perfused vessels, and heterogeneity index, as well as vascular-waterfall parameters, including estimated critical closing pressure, estimated mean systemic filling pressure, and the Pcc-Pmsf gradient, will be measured at baseline, 3 hours, and 6 hours after initiation of dexmedetomidine. Systemic hemodynamic, perfusion, vasopressor, PiCCO-derived, sedation-related, and safety outcomes will also be collected.\n\nThe primary objective is to characterize immediate changes in sublingual microcirculation and vascular-waterfall physiology after dexmedetomidine administration and to provide preliminary data for future controlled studies.",[65,66,67],[151,71,72,73,74,75,76,77,78,79,80,152,153,154,155],"dexmedetomidine","sedation","bradycardia","hypotension","norepinephrine",{"date":84,"type":42},{"date":86,"type":21},{"date":88,"type":21},{"name":48,"class":49},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":167,"targetDuration":169,"studyType":170,"phases":4,"briefSummary":171,"conditions":172,"keywords":176,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":50},"100642676","shear-wave-elastography-of-peripheral-nerves-for-early-diagnosis-of-icu-acquired-weakness-100642676","NCT07594249","Shear Wave Elastography of Peripheral Nerves for Early Diagnosis of ICU-acquired Weakness","Clinical Value of Shear Wave Elastography of Peripheral Nerves for the Early Diagnosis of ICU-Acquired Weakness: A Prospective Observational Pilot Study","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Newly admitted to ICU with an expected ICU stay \\> 7 days;\n3. Initiated on mechanical ventilation within 24 hours of admission, with an expected ventilation duration \\> 48 hours;\n4. Patient or legally authorized representative provides written informed consent.\n\nExclusion Criteria:\n\n1. Known pre-existing neuromuscular diseases (e.g., myasthenia gravis, Guillain-Barré syndrome, amyotrophic lateral sclerosis);\n2. Pre-existing limb dysfunction that would interfere with muscle strength assessment (e.g., hemiplegia, paraplegia, severe arthritis);\n3. Presence of acute trauma, surgery, skin breakdown, infection, or severe edema at the measurement sites (wrist, elbow, ankle) that would interfere with ultrasound probe placement;\n4. Pregnant or lactating women;\n5. Any other condition that the investigator believes would make the patient unsuitable for the study.",{"count":168,"type":21},98,"28 Days","OBSERVATIONAL","This study aims to determine whether shear wave elastography (SWE), a non-invasive ultrasound technique that measures nerve stiffness, can help detect ICU-acquired weakness (ICU-AW) early in critically ill patients. Adults receiving mechanical ventilation in the ICU will undergo ultrasound examinations of the median and tibial nerves on Days 1, 4, and 7. The study will evaluate whether early changes in nerve elasticity can predict ICU-AW, which is usually diagnosed later using a muscle strength score that requires patient cooperation.",[173,174,175],"ICU-acquired Weakness","Critical Illness Polyneuropathy","Critical Illness Myopathy",[177,178,179,180,181],"Shear Wave Elastography","Peripheral Nerve","Ultrasonography","Critical Care","Early Diagnosis","2026-06-13",{"date":184,"type":42},"2026-06-16",{"date":186,"type":21},"2026-07-01",{"date":188,"type":21},"2027-06-30",{"name":48,"class":49},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":50},"100638311","changes-in-regional-ventilation-perfusion-match-following-percutaneous-transluminal-angioplasty-for-arteriovenous-graft-thrombosis-100638311","NCT07613632","Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis","Changes in Regional Ventilation-Perfusion Match Following Percutaneous Transluminal Angioplasty for Arteriovenous Graft Thrombosis: A Prospective Observation Pilot Study","Inclusion Criteria\n\n1. Age ≥ 18 years.\n2. Diagnosis of end-stage renal disease receiving maintenance hemodialysis.\n3. Documented AVG thrombosis requiring PTA.\n4. Able to cooperate and tolerate EIT monitoring.\n5. Provided written informed consent.\n\nExclusion Criteria\n\n1. Severe respiratory failure incompatible with supine position.\n2. Thoracic skin condition or deformity preventing EIT electrode placement.\n3. Acute pulmonary embolism or acute pulmonary edema before procedure.\n4. NYHA Class IV heart failure or hemodynamic instability.\n5. Pregnancy or breastfeeding.\n6. Any other circumstance judged unsuitable by investigator.",{"count":61,"type":21},"Patients with end-stage renal disease (ESRD) often require arteriovenous grafts (AVG) for hemodialysis. AVG thrombosis is a common complication, usually managed by percutaneous transluminal angioplasty (PTA) to restore blood flow. PTA achieves patency by balloon-mediated compression and fragmentation of thrombus. Small thrombus fragments may enter the venous circulation and cause transient pulmonary microembolism, leading to ventilation-perfusion (V\u002FQ) mismatch. This study uses electrical impedance tomography (EIT) to noninvasively monitor short-term changes in regional ventilation and perfusion during and after PTA, exploring the immediate pulmonary physiological consequences of thrombus fragmentation and revascularization in dialysis patients.",[200,201],"Arteriovenous Graft Thrombosis","End Stage Renal Disease on Dialysis",[203,32,204,205,206,207,208],"Percutaneous Transluminal Angioplasty","Ventilation-Perfusion Matching","Pulmonary Microembolism","Dead Space","Shunt","Pilot Study","RECRUITING","2026-05-23",{"date":212,"type":42},"2026-05-29",{"date":214,"type":42},"2024-10-24",{"date":88,"type":21},{"name":48,"class":49},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":237,"leadSponsor":238,"locationsCount":50},"100638043","effect-of-shenfu-injection-on-the-vascular-waterfall-phenomenon-in-patients-with-septic-shock-100638043","NCT07603024","Effect of Shenfu Injection on the Vascular Waterfall Phenomenon in Patients With Septic Shock","Effect of Shenfu Injection on the Vascular Waterfall Phenomenon in Patients With Septic Shock: A Prospective Pilot Study","nclusion Criteria Septic shock diagnosed according to Sepsis-3 criteria after adequate fluid resuscitation.\n\nAge ≥ 18 years. Within 24 hours of ICU admission. Receiving norepinephrine ≥ 0.10 µg\u002Fkg\u002Fmin to maintain mean arterial pressure ≥ 65 mmHg.\n\nHemodynamically stable without vasopressor dose adjustment for ≥ 30 minutes before baseline measurement.\n\nEndotracheal intubation with controlled mechanical ventilation under continuous sedation and analgesia.\n\nPresence of both arterial and central venous catheters with PiCCO monitoring capability.\n\nWritten informed consent obtained from the patient or legally authorized representative.\n\nExclusion Criteria Cardiogenic shock as primary diagnosis or cardiac index \\\u003C 2.2 L\u002Fmin\u002Fm² after optimization.\n\nSevere pulmonary bullae, pneumothorax, or conditions precluding safe inspiratory hold maneuvers.\n\nPregnancy or lactation. Expected ICU stay \\\u003C 48 hours or limitation of life-sustaining therapy. Known allergy or contraindication to Shenfu Injection or its ingredients (e.g., ginseng, aconitum).",{"count":61,"type":21},[24],"This prospective single-center clinical trial aims to evaluate the circulatory and microcirculatory effects of Shenfu Injection in patients with septic shock. The study focuses on the vascular waterfall phenomenon, which describes the relationship between arterial and venous pressures in the microcirculation.\n\nEligible participants with septic shock will receive an intravenous infusion of 100 mL Shenfu Injection (manufactured by China Resources Sanjiu Pharmaceutical Co., Ltd.). Hemodynamic and oxygen metabolism parameters will be measured before and 3 hours after treatment. The main goal is to determine whether Shenfu Injection influences the vascular waterfall difference, expressed as the gap between critical closure pressure and mean systemic filling pressure.\n\nThis study will also record changes in cardiac index, systemic vascular resistance, blood lactate, venous oxygen saturation, and norepinephrine requirement. Findings will provide preliminary clinical evidence about the role of Shenfu Injection in circulatory regulation during septic shock and help design future randomized controlled studies.",[65],[229,230,65,231,232,36],"Shenfu Injection","Traditional Chinese Medicine","Vascular Waterfall Phenomenon","Critical Closure Pressure","2026-05-18",{"date":235,"type":42},"2026-05-22",{"date":186,"type":21},{"date":188,"type":21},{"name":48,"class":49},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":254,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":50},"100592197","focused-ultrasound-spleen-stimulation-and-inflammation-in-septic-shock-100592197","NCT06990295","Focused Ultrasound Spleen Stimulation and Inflammation in Septic Shock","Effects of Focused Ultrasound Spleen Neuromodulation on Inflammatory Cytokine Levels in Patients With Septic Shock: A Randomized Controlled Pilot Trial","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of sex\n* Diagnosed with septic shock according to Sepsis-3 criteria: Sequential Organ Failure Assessment (SOFA) score ≥ 2 and requiring vasopressor support to maintain a mean arterial pressure (MAP) ≥ 65 mmHg.\n* Admitted to the ICU within 24 hours of septic shock diagnosis\n* Expected to require intensive care for at least 72 hours\n* Informed consent obtained from the patient or legal representative\n\nExclusion Criteria:\n\n* Known pregnancy or breastfeeding\n* Participation in another interventional clinical trial within 30 days\n* Known immunodeficiency or ongoing immunosuppressive therapy\n* Malignancy with life expectancy \\\u003C 6 months\n* Contraindications to focused ultrasound (e.g., splenic trauma, splenectomy, local skin infection)\n* Do-not-resuscitate (DNR) order or expected death within 24 hours\n* Any other condition deemed unsuitable for participation by the investigators",{"count":247,"type":21},40,[24],"This study evaluates the safety and effectiveness of focused ultrasound spleen neuromodulation in patients with septic shock, a life-threatening condition characterized by excessive inflammation and organ dysfunction. The primary objective is to determine whether non-invasive, focused ultrasound stimulation of the spleen can reduce circulating inflammatory cytokine levels in this patient population.\n\nEligibility Criteria:\n\nAdults aged 18 years or older Diagnosed with septic shock and admitted to the ICU within 24 hours Expected to require intensive care for at least 72 hours\n\nStudy Protocol:\n\nParticipants will be randomly assigned to one of two groups:\n\nIntervention Group: Will receive standard septic shock care plus twice-daily focused ultrasound stimulation over the spleen for five days, using a portable device.\n\nControl Group: Will receive standard septic shock care alone. Blood samples will be collected at baseline and Day 5 to measure inflammatory cytokine levels, including TNF-α, IL-1β, IL-6, and IL-10. Additional assessments will include lymphocyte subpopulations, organ function scores, ICU length of stay, 28-day mortality, and adverse events.\n\nOutcome Measures:\n\nPrimary: Change in levels of inflammatory cytokines on Day 5. Secondary: Changes in organ function (SOFA score), ICU length of stay, 28-day survival, and safety\u002Ftolerability of the intervention.",[65,251,252,253,180],"Inflammatory Cytokines","Spleen Neuromodulation","Focused Ultrasound",[65,253,252,251,180,255,208],"Immune Modulation","2026-05-15",{"date":258,"type":42},"2026-05-19",{"date":260,"type":42},"2025-07-25",{"date":262,"type":21},"2026-12-31",{"name":48,"class":49},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":271,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":282,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":291,"locationsCount":50},"100639824","case-based-learning-for-bedside-lung-ultrasound-teaching-in-icu-100639824","NCT07594470","Case-Based Learning for Bedside Lung Ultrasound Teaching in ICU","CBL Mode in Clinical Teaching of Bedside Lung Ultrasound in Intensive Care Unit: A Randomized Controlled Study","Inclusion Criteria:\n\n* Standardized residency trainees currently rotating in the Intensive Care Unit (ICU), specializing in Internal Medicine, Surgery, Emergency Medicine, Anesthesiology, or General Practice.\n* Have completed institutional basic ultrasound theory training or possess preliminary ultrasound knowledge.\n* Voluntarily participate and provide written informed consent.\n* Able to complete the entire teaching and evaluation schedule (including written test and OSCE).\n\nExclusion Criteria:\n\n* Prior formal training or certification in lung\u002Fcritical care ultrasound.\n* Unable to complete the study period due to rotation scheduling or absence.\n* Decline or withdraw informed consent.",true,{"count":273,"type":21},106,[24],"This single-center randomized controlled study aims to evaluate the effectiveness of Case-Based Learning (CBL) compared with traditional teaching in clinical training of bedside lung ultrasound (BLUE) for emergency medicine residents and medical students. The hypothesis is that CBL improves theoretical understanding, practical ultrasound skills, and clinical reasoning in emergency settings.",[277,278,279,280,281],"Medical Education","ICU","Emergency Medicine","Lung Ultrasound","Case-based Learning",[283,284,285,279,286,36],"Case-based learning","Bedside Lung Ultrasound (BLUE)","Case-Based Learning (CBL)","Critical ultrasonography","2026-05-14",{"date":233,"type":42},{"date":186,"type":21},{"date":188,"type":21},{"name":48,"class":49},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":50},"100602743","hemoadsorption-for-severe-ischemic-stroke-100602743","NCT07127484","Hemoadsorption for Severe Ischemic Stroke","Efficacy and Safety of Hemoadsorption for Severe Ischemic Stroke","Inclusion Criteria:\n\n1.18 years ≤ age \\\u003C 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following:\n\n1. 15≤ NIHSS score ≤32;\n2. 3\\\u003CGCS score ≤12;\n3. CT hypodensity area \\>1\u002F2 of the MCA territory; 4.hs-CRP ≥2 mg\u002FL at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.\n\nExclusion Criteria:\n\n1. Hemorrhagic transformation of PH2 type prior to randomization;\n2. Brain herniation or decompressive craniectomy performed before randomization;\n3. Hemodynamic instability refractory to medical correction (systolic blood pressure \\\u003C70 mmHg or diastolic blood pressure \\\u003C50 mmHg) or decompensated heart failure (NYHA Class III or IV);\n4. Severe hepatic impairment (defined as ALT \\>2 times the upper limit of normal or AST \\>2 times the upper limit of normal) and renal impairment (defined as serum creatinine \\>1.5 times the upper limit of normal or estimated glomerular filtration rate \\[eGFR\\] \\\u003C50 mL\u002Fmin);\n5. Coagulopathy or thrombocytopenia (platelet count \\\u003C100×10⁹\u002FL);\n6. Deep vein thrombosis (DVT) of the lower extremities before randomization;\n7. Life expectancy \\\u003C90 days due to malignancy;\n8. Participation in another drug or device clinical trial within the past 30 days or ongoing enrollment in such trials;\n9. Women of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or pregnant\u002Flactating women;\n10. Absolute contraindications to hemoadsorption therapy.","80 Years",{"count":301,"type":21},116,[24],"This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke",[305,306],"Ischemic Stroke","Hemoadsorption","2026-05-13",{"date":256,"type":42},{"date":310,"type":42},"2026-01-05",{"date":312,"type":21},"2027-02-28",{"name":48,"class":49},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":329,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":4},"100610784","assessing-local-hypothermia-and-endovascular-recanalization-for-acute-stroke-with-a-large-core-infarction-100610784","NCT07232082","Assessing Local Hypothermia and Endovascular Recanalization for Acute Stroke With a Large Core Infarction","Assessing Local Hypothermia and Endovascular Recanalization for Acute Stroke With a Large Core Infarction-A Multicenter, Prospective, Open-label, Blinded-Endpoint, Randomized Controlled Trial","RESCUE-LCI","Inclusion Criteria:\n\nGeneral Inclusion Criteria：\n\n1. Age ≥18 years old.\n2. The National Institutes of Health Stroke Scale (NIHSS) score was ≥6 points before randomization.\n3. Time from symptom onset to randomization ≤24h.\n4. Patients or their guardians can understand the purpose of the trial, voluntarily participate and sign a written informed consent, and are capable of receiving clinical follow-up.\n\nSpecific Neuroimaging Inclusion Criteria\n\n1. Prior to randomization, CTA, MRA, or DSA confirmed the presence of anterior circulatory large vessel occlusion (internal carotid artery or M1segment).\n2. NCCT ASPECTS value of 3 to 5 based on findings from non-contrast CT within 24 hours after stroke onset (defined as the time the patient was last known to be well), with no limitation with respect to infarct-core volume;\n3. NCCT ASPECTS value of 0 to 2 based on findings from non-contrast CT within 24 hours after stroke onset and an infarct-core volume between 70 ml and 100 ml;\n4. NCCT ASPECTS value greater than 5 based on findings from non-contrast CT after stroke onset and an infarct-core volume of 70 to 100 ml.\n\nExclusion Criteria:\n\n1. Pre stroke mRS\\>1 score.\n2. Multivessel Occlusion\n3. Concomitant untreated intracranial aneurysms, intracranial tumors (with the exception of small meningiomas), or intracranial vascular malformations.\n4. History of intracranial hemorrhage within 6 months, including parenchymal hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n5. History of gastrointestinal hemorrhage, genitourinary bleeding, acute myocardial infarction (AMI), cranial trauma, or having undergone major surgical procedures within the past month.\n6. The presence of active bleeding, severe anemia, coagulation dysfunction, or an uncorrected bleeding tendency (platelet count \\\u003C 40,000 \u002Fμl, uncorrected INR\\>2.0).\n7. Patients with heart function of grade 1 or above, or with a clear history of acute or chronic heart dysfunction, are at greater risk of acute heart failure or fluid perfusion intolerance as determined by clinicians.\n8. Severe heart, liver, kidney disease.\n9. Known allergy to contrast media or related medications.\n10. Refractory hypertension uncontrolled by medication (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg).\n11. glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL；\n12. Pregnancy or lactation；\n13. the expected survival time is less than 12 months.\n14. Participating in other clinical trials, in the investigational phase or in the follow-up phase.\n15. Other conditions deemed by investigators to pose significant risks or render participation unsuitable (e.g. inability to comply due to psychiatric\u002Fcognitive\u002Femotional disorders).",{"count":323,"type":21},322,[24],"A multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial to assess the effectiveness and safety of catheter-based focal intracranial hypothermia combined with endovascular reperfusion therapy for acute patients with a Large Core Infarction.",[327,328],"Stroke","Large Ischemic Core",[330,331],"endovascular therapy","Hypothermia","2026-04-27",{"date":334,"type":42},"2026-04-28",{"date":336,"type":21},"2026-05-01",{"date":338,"type":21},"2027-04-07",{"name":48,"class":49},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":50},"100527109","endovascular-therapy-versus-best-medical-treatment-for-acute-large-vessel-occlusion-stroke-with-low-nihss-100527109","NCT06143488","Endovascular Therapy Versus Best Medical Treatment for Acute Large Vessel Occlusion Stroke With Low NIHSS","1. Aged 18 years or older;\n2. The time from onset of acute ischemic stroke to arterial puncture is within 24 hours. Onset time is defined as the patient's Last Known Well (LKW);\n3. Low NIHSS score (2-5 points), with at least one of the following items:\n\n   1. Altered mental status (lethargy or worse);\n   2. Facial palsy (facial weakness score ≥ 1 point);\n   3. Motor dysfunction (limb weakness score ≥ 1 point);\n   4. Aphasia (language disturbance score ≥ 1 point);\n   5. Hemispatial neglect (neglect score ≥ 1 point);\n4. Intracranial internal carotid artery, proximal M1 or M2 segment of middle cerebral artery occlusion (excluding tandem lesions) confirmed by cerebral CTA\u002FMRA\u002FDSA before randomization, which is identified as the culprit vessel for stroke;\n5. All patients receive CTP\u002FMR perfusion imaging, with a volume of perfusion delay (Tmax\\>6 s) ≥ 50 mL;\n6. Written informed consent is obtained from the patient or legal surrogate, with agreement for long-term follow-up.",{"count":347,"type":21},264,[24],"Patients presenting with mild symptoms of acute ischemic stroke are common and account for approximately half of all acute ischemic stroke. About 30% of patients with minor stroke have a 90-day functional disability. Radiologically proven a large vessel occlusion (LVO) in patients with minor stroke is a well-established predictor of poor outcomes, while the poor outcomes following best medical management in patients with minor stroke with the underlying presence of a LVO are mainly driven by the occurrence of early neurological deterioration (END).\n\nConsidering the well-known strong association between lack of arterial recanalization and END, endovascular therapy (EVT) appears as an attractive option to improve functional outcomes for LVO-related patients with stroke with mild symptoms. Whether EVT is safe and effective in patients with mild stroke with an LVO is currently debated, since these patients were typically excluded from the pivotal EVT trials.\n\nThe current study aimed to further test the hypothesis that endovascular therapy would be superior to medical management with respect to functional recovery among low NIHSS patients caused by acute large-vessel occlusion in the anterior circulation.",[351,352,353],"Acute Ischemic Stroke","Mild Neurocognitive Disorder","Thrombectomy",{"date":355,"type":42},"2026-04-30",{"date":357,"type":42},"2024-02-07",{"date":359,"type":21},"2028-03-31",{"name":48,"class":49},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":375,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":384},"100527997","rescue-endovascular-therapy-for-progressive-acute-mild-ischemic-stroke-with-large-vascular-occlusion-100527997","NCT06155032","Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion","Study of Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion--- A Multi-centered, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial (RESCUE END-LOW)","Inclusion Criteria:\n\nGeneral Inclusion Criteria：\n\n* Age ≥ 18 years；\n* Presenting with symptoms consistent with an AIS and the initial NIHSS score \\\u003C6 points；\n* Symptom progression within 7 days of first onset；\n* Randomization can be finished \\> 24 hours of stroke onset (stroke onset time is defined as last known well time)；\n* Symptom progression to randomization time ≤ 24 hours；\n* NIHSS score before randomization ≥ 6 points；\n* Informed consent signed.\n\nSpecific Neuroimaging Inclusion Criteria\n\n* CTA or MRA proved occlusion of Internal Carotid Artery (ICA) terminal or M1 segment of Middle Cerebral Artery;\n* The progression of symptoms is caused by the recurrence of cerebrovascular diseases in the same vascular region, or the pathogenesis is caused by reduced blood flow perfusion;\n* NCCT ASPECTS before randomization ≥ 6\n* CTP or MRP assessment shows low perfusion in the target vessel area, and meets the following criteria: core infarction volume is less than 50ml, mismatch rate is greater than or equal to 1.8, and mismatch volume is greater than 15ml.\n\nExclusion Criteria:\n\n* Pre-stroke mRS score \\>1;\n* Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes;\n* The target vessel may have factors that may prevent it from completing endovascular treatment, such as a diameter less than 1.5mm, a tortuous vascular pathway, difficulty in reaching the target position with instruments, or difficulty in recovery;\n* Severe stenosis or occlusion of multiple blood vessels;\n* Combined with untreated intracranial aneurysms, intracranial tumors (excluding small meningiomas), or intracranial vascular malformations;\n* Intracranial hemorrhage within 6 months, including cerebral parenchymal hemorrhage, ventricular hemorrhage, and subarachnoid hemorrhage;\n* Have had gastrointestinal or urinary system bleeding, acute myocardial infarction, traumatic brain injury, or undergone major surgical procedures within the past month;\n* Known hemorrhagic tendency (including but not limited to): Baseline platelet count \\\u003C40×109\u002FL; on anticoagulant therapy with warfarin and International Normalized Ratio (INR) \\> 2 (Patients with no history or suspected coagulopathy do not need to wait for laboratory results of INR or APTT prior to enrollment) Severe heart, liver, kidney function damage or other severe late stage diseases of the system;\n* Known allergies to treatment related drugs such as iodine contrast agents, etc; Known severe allergy (more than a rash) to contrast media uncontrolled by medications;\n* Refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg);\n* Uncontrolled blood sugar abnormalities (less than 2.8mmol\u002Fl or greater than 22.2mmol\u002Fl);\n* Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test;\n* The expected survival time is less than 1 year (such as complicated with malignant tumor, serious heart and lung diseases, etc.)\n* Participation in other interventional randomized clinical trials that may confound outcome assessment of the trial\n* Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and\u002For follow the study procedures and\u002For follow up due to mental disorders, cognitive or emotional disorders)",{"count":369,"type":21},272,[24],"Endovascular therapy (EVT) added on best medical management is currently recommended in acute large vascular occlusion (LVO) stroke patients with National Institutes of Health Stroke Scale (NIHSS) score \\>5. Thus, a sizeable fraction of patients with a minor stroke that do not undergo cerebrovascular screening may experience an early neurological deterioration (END) due to LVO, possibly leading to poor long-term functional outcome. However, whether these patients may still benefit from a rescue EVT is unknown, especially in a late window (\\>24 hours). In this study, the investigators assume that best medical management plus EVT might be superior than best medical management alone in a late window for minor stroke patients who have experienced an LVO and END. The primary objective of the study was to establish the safety and efficacy of EVT in a late window for minor stroke patients in the anterior circulation who experienced an LVO and END.",[373,374],"Stroke, Ischemic","Cerebrovascular; Disorder, Occlusive",[330,376,377],"mild stroke","neurological deterioration",{"date":355,"type":42},{"date":380,"type":42},"2024-01-04",{"date":382,"type":21},"2027-03-30",{"name":48,"class":49},7,{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":22,"phases":394,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":4},"100634238","phase-4-efficacy-and-safety-of-triple-therapy-with-dulaglutide-sglt2-inhibitors-and-finerenone-in-chinese-adults-with-type-2-diabetes-and-chronic-kidney-disease-100634238","NCT07537088","Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease","Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study","Inclusion Criteria:\n\n* 1.Patients aged ≥18 years with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD)\n* 2.Hemoglobin A1c (HbA1c) 7.0%-11%\n* 3.Urine albumin-to-creatinine ratio (UACR) 300-5000 mg\u002Fg\n* 4.Body mass index (BMI) 21-45 kg\u002Fm²\n* 5.Having received combination therapy with SGLT2 inhibitor and finerenone for 3 months or longer, on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi)\n* 6.Sign the informed consent, understand the procedures and methods of this trial and willing to strictly comply with the clinical trial protocol\n\nExclusion Criteria:\n\n* 1.Pregnant or lactating women, or women of childbearing potential unwilling to use reliable contraception\n* 2.History of definite contraindications or intolerance to glucagon-like peptide-1 receptor agonists (GLP-1RA), SGLT2 inhibitors, or finerenone\n* 3.Type 1 diabetes\n* 4.History of diabetic ketoacidosis (DKA) within the past 6 months\n* 5.Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m²\n* 6.Hospitalization within 30 days prior to screening for acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery\n* 7.Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg (mean of three supine measurements) during screening\n* 8.Symptomatic hypotension and\u002For systolic blood pressure \\\u003C90 mmHg at screening, or patients judged by the investigator to have hypovolemia\n* 9.Serum potassium \\>5.0 mmol\u002FL at screening\n* 10.Current use or use within 3 months prior to screening of GLP-1 receptor agonists or other mineralocorticoid receptor antagonists (e.g., spironolactone)\n* 11.Patients receiving or with clear clinical indications requiring systemic immunosuppressive therapy (including but not limited to prednisone, cyclosporine, etc.) for other kidney diseases (e.g., primary or secondary glomerulonephritis, lupus nephritis)\n* 12.History of recurrent urinary tract or genital infections (as judged by the investigator)\n* 13.Life expectancy \\\u003C1 year at screening\n* 14.Confirmed malignancy\n* 15.Participation in another clinical trial within 3 months prior to screening\n* 16.Any other condition judged by the investigator as unsuitable for participation in this clinical trial.",{"count":393,"type":21},468,[395],"PHASE4","The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese adults with Type 2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease(CKD). Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participants will be randomly assigned to either continue the original regimen or to receive add-on therapy with dulaglutide.The study will last for 26 weeks, with participants required to attend scheduled visits for efficacy and safety assessments at Week 13 (±1 week) and Week 26 (±1 week, final visit).",[398,399],"T2DM (Type 2 Diabetes Mellitus)","CKD - Chronic Kidney Disease","2026-04-17",{"date":402,"type":42},"2026-04-22",{"date":404,"type":21},"2026-05",{"date":406,"type":21},"2027-07",{"name":48,"class":49},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":169,"studyType":170,"phases":4,"briefSummary":416,"conditions":417,"keywords":421,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":50},"100634644","the-feasibility-of-pulmonary-perfusion-assessment-using-sodium-bicarbonate-contrast-with-electrical-impedance-tomography-a-prospective-pilot-study-100634644","NCT07542366","The Feasibility of Pulmonary Perfusion Assessment Using Sodium Bicarbonate Contrast With Electrical Impedance Tomography: A Prospective Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admitted to the intensive care unit (ICU)\n* Receiving invasive mechanical ventilation with controlled or assisted-controlled mode\n* Presence of a central venous catheter suitable for contrast bolus injection\n* Hemodynamically stable (no ongoing cardiopulmonary resuscitation; no uncontrolled shock judged by treating physician)\n* Expected to remain on mechanical ventilation for the duration of the EIT examination\n* Written informed consent obtained from the patient or legally authorized representative\n\nExclusion Criteria:\n\n* Known pregnancy\n* Known allergy, intolerance, or contraindication to sodium bicarbonate or hypertonic saline\n* Severe arrhythmia or unstable cardiovascular status in which small bolus injection is deemed unsafe by the treating physician\n* Uncontrolled agitation or conditions that preclude correct EIT belt placement (e.g., extensive chest wounds, large chest dressings, chest wall deformity that prevents belt use)\n* Implanted electronic devices or metallic implants in the thoracic area considered a contraindication to EIT by the manufacturer's instructions\n* End-stage disease with expected survival of only a few hours, in whom participation is not appropriate as judged by the treating physician\n* Participation in another interventional trial that, in the opinion of the investigator, could interfere with EIT measurements or safety assessment",{"count":415,"type":21},41,"The goal of this observational pilot study is to learn if sodium bicarbonate can be used safely and effectively as a contrast agent to map lung blood flow using electrical impedance tomography (EIT) in adults on mechanical ventilation. Electrical impedance tomography (EIT) is a bedside imaging method that uses a soft belt with small sensors around the chest to track changes in electrical signals related to breathing and blood flow.\n\nThe main questions are:\n\nDoes sodium bicarbonate create clear, readable lung blood flow images with EIT? Are these images similar in quality and pattern to images made with hypertonic saline (10% sodium chloride)? Is the short-term safety profile acceptable, including effects on blood pressure, heart rhythm, and blood tests?\n\nResearchers will compare two contrast agents within the same participant to see if image quality and lung blood flow patterns match:\n\nHypertonic saline (10% sodium chloride) Sodium bicarbonate (5%)\n\nParticipants will:\n\nHave an EIT belt placed around the chest during routine ICU care Pause the ventilator briefly during image capture to reduce motion Receive two small intravenous boluses through an existing central line, one of hypertonic saline and one of sodium bicarbonate, with time between doses Have routine monitoring of vital signs; blood gases and electrolytes may be checked per clinical care Be observed for any short-term side effects Findings from this study will show whether sodium bicarbonate is a practical and safe option for EIT-based lung blood flow assessment and will guide larger future studies.",[35,418,419,67,420],"Acute Respiratory Distress Syndrome (ARDS)","Pneumonia","Feasibility of Contrast-enhanced Electrical Impedance Tomography (EIT) for Pulmonary Perfusion Assessment in Mechanically Ventilated Adults",[422,423,424,425,426,427,428,429,430,431],"Electrical Impedance Tomography (EIT)","Pulmonary Perfusion","Contrast-Enhanced EIT","Sodium Bicarbonate Contrast","Hypertonic Saline (10% NaCl)","First-Pass Impedance Signal","Mechanical Ventilation","Intensive Care Unit (ICU)","Ventilation-Perfusion (V\u002FQ) Matching","Feasibility Study","2026-04-14",{"date":434,"type":42},"2026-04-21",{"date":436,"type":42},"2024-09-26",{"date":438,"type":21},"2026-09-25",{"name":48,"class":49},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":4},"100631503","phase-2-delayed-versus-early-antihyperglycemic-treatment-for-severe-stroke-100631503","NCT07501533","Delayed Versus Early Antihyperglycemic Treatment for Severe Stroke","Delayed Versus Early Antihyperglycemic Treatment for Severe Stroke: A Prospective, Randomized, Controlled, Open-Label, Blinded-Endpoint Clinical Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Severe stroke within 24 hours of onset, meeting one of the following criteria:\n\n1）Severe ischemic stroke: Glasgow Coma Scale (GCS) score ≤ 12 or National Institutes of Health Stroke Scale (NIHSS) score ≥ 15 or CT hypodensity \\> 1\u002F3 of middle cerebral artery (MCA) territory; 2）Severe intracerebral hemorrhage: Supratentorial hematoma volume ≥ 30 mL (thalamic hemorrhage ≥ 10 mL) or infratentorial hematoma volume ≥ 10 mL (brainstem hemorrhage ≥ 5 mL); 3）Aneurysmal subarachnoid hemorrhage; 3. Blood glucose level \\> 10 mmol\u002FL at randomization; 4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Known history of type 1 diabetes mellitus;\n2. Known allergy to insulin or diagnosis of insulinoma;\n3. Pre-stroke modified Rankin Scale (mRS) score \\> 1;\n4. Hemodynamic instability refractory to medical treatment (systolic blood pressure \\\u003C 90 mmHg or diastolic blood pressure \\\u003C 60 mmHg);\n5. Decompensated heart failure (New York Heart Association \\[NYHA\\] class III or IV);\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin;\n7. Expected survival \\\u003C 90 days due to malignancy;\n8. Participation in another drug or device clinical trial within the past 30 days;\n9. Women of childbearing potential who refuse to use effective contraception despite negative pregnancy test, pregnant women, or breastfeeding women.",{"count":448,"type":21},200,[450],"PHASE2","This study is a exploratory, randomized, controlled, open-label, blinded-endpoint Phase II clinical trial designed to evaluate whether delaying antihyperglycemic treatment for 72 hours improves neurological outcomes in patients with severe stroke and hyperglycemia.\n\nA total of 426 patients with severe stroke (including ischemic stroke, intracerebral hemorrhage, or aneurysmal subarachnoid hemorrhage) within 24 hours of onset and blood glucose \\>10 mmol\u002FL at randomization will be enrolled. Participants will be randomly assigned in a 1:1 ratio to either delayed antihyperglycemic treatment (initiated on Day 4) or early antihyperglycemic treatment (initiated on Day 1). Glycemic control targets (7.8-10.0 mmol\u002FL) and insulin therapy follow current clinical guidelines.\n\nThe primary outcome is the incidence of poor functional outcome (modified Rankin Scale score ≥ 3) at 90 days. Secondary outcomes include mortality, NIHSS score, GCS score, ICU length of stay, and safety events such as hypoglycemia and infections.\n\nThe study aims to provide evidence on the optimal timing of glycemic control in severe stroke patients with stress hyperglycemia.",[453],"Severe Stroke","2026-03-26",{"date":456,"type":42},"2026-03-30",{"date":458,"type":21},"2026-04-01",{"date":460,"type":21},"2027-11-30",{"name":48,"class":49},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":299,"enrollmentInfo":470,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":472,"conditions":473,"keywords":476,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":50},"100595501","inferior-vena-cava-collapsibility-index-and-intradialytic-hypotension-100595501","NCT07033273","Inferior Vena Cava Collapsibility Index and Intradialytic Hypotension","The Predictive Value of the Inferior Vena Cava Collapsibility Index for Intradialytic Hypotension: A Prospective Multicenter Observational Stud","IVC-HD","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed with end-stage renal disease (ESRD).\n* Undergoing regular hemodialysis for at least three months.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Hemodynamically unstable patients or those requiring vasopressor support.\n* Patients with severe cardiac conditions, including congestive heart failure -classified as NYHA Class III-IV or severe valvular disease.\n* Patients with known allergies to dialysis filters.\n* Dialysis sessions terminated for reasons unrelated to hypotension (e.g., technical issues, patient request).\n* Patients who withdraw informed consent during the study.\n* Use of antihypertensive medications during dialysis sessions.\n* Inability to undergo ultrasound assessment due to factors such as severe obesity or wounds obstructing access.",{"count":471,"type":21},188,"This multicenter, prospective observational study aims to evaluate the predictive value of the Inferior Vena Cava Collapsibility Index (IVCCI), along with IVC maximum diameter (IVCmax) and IVC minimum diameter (IVCmin), for intradialytic hypotension in patients undergoing maintenance hemodialysis. The study will be conducted at The First Affiliated Hospital of Wannan Medical College, Wuhu City Second People's Hospital, Wuhu Hospital of Chinese Traditional Medicine, Wuhu Jinghu District Hospital, and Wuhu Guangji Hospital. Eligible participants are adults aged 18 years or older with diagnosed end-stage renal disease (ESRD), receiving regular hemodialysis for at least three months. Patients with acute kidney injury, severe cardiac conditions, or other factors likely to influence results will be excluded.\n\nUltrasound measurements of IVCCI, IVCmax, and IVCmin will be performed once, precisely at 1 hour after dialysis initiation. IVCmax will be measured during inspiration when the IVC is at its largest, and IVCmin during expiration when it is at its smallest. Blood pressure will be monitored continuously during the procedure. The primary objective is to assess the sensitivity, specificity, and optimal cutoff values of IVCCI, IVCmax, and IVCmin for predicting hypotension, aiming to provide a simple and non-invasive tool to facilitate personalized dialysis management and reduce intradialytic hypotension. A sample size of 188 participants is estimated, with data analyzed using ROC curves and multivariate regression methods. The study protocol adheres to ethical standards and regulatory requirements, demonstrating potential to improve patient safety and treatment outcomes.",[474,475],"End-Stage Renal Disease Requiring Haemodialysis","Intradialytic Hypotension",[475,477,478,479,480],"Hemodialysis","Inferior Vena Cava Collapsibility Index","Blood Pressure Prediction","Vascular Ultrasonography","2025-06-14",{"date":483,"type":42},"2025-06-24",{"date":485,"type":42},"2025-01-27",{"date":487,"type":21},"2025-07-31",{"name":48,"class":49},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":299,"enrollmentInfo":497,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":499,"conditions":500,"keywords":502,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":50},"100595500","predictive-value-of-carotid-ultrasonography-for-intradialytic-hypotension-100595500","NCT07033260","Predictive Value of Carotid Ultrasonography for Intradialytic Hypotension","The Predictive Value of Carotid Corrected Flow Time and Peak Flow Velocity Variability for Intradialytic Hypotension: A Prospective Multicenter Observational Study","CUPID","Inclusion Criteria:\n\nAdults aged 18 to 80 years. Diagnosed with end-stage renal disease (ESRD). Undergoing maintenance hemodialysis for more than three months. Willing and able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\nPatients with significant carotid artery stenosis due to heavy atherosclerotic plaque (defined as more than 70% stenosis confirmed by ultrasound or angiography).\n\nHemodynamically unstable patients or those requiring vasopressor support. Patients with significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia).\n\nDialysis sessions terminated for reasons unrelated to hypotension (e.g., technical issues, patient request).\n\nUse of antihypertensive medications during dialysis sessions. Inability to undergo ultrasound assessment due to factors such as severe obesity or wounds obstructing access.\n\nPatients who withdraw informed consent during the study.",{"count":498,"type":21},183,"This multicenter, prospective observational study aims to evaluate the predictive value of carotid corrected flow time (FTc) and peak flow velocity variability (PFVV) for hypotension during maintenance hemodialysis. Conducted at The First Affiliated Hospital of Wannan Medical College, Wuhu City Second People's Hospital, Wuhu Hospital of Chinese Traditional Medicine, Wuhu Jinghu District Hospital, and Wuhu Guangji Hospital, the study will include adult patients (≥18 years) with end-stage renal disease (ESRD) on long-term hemodialysis for at least three months. Patients with acute kidney injury, severe cardiac conditions, or other factors affecting results will be excluded. Ultrasound assessments of FTc and PFVV will be performed once, at 1 hour after dialysis initiation. Blood pressure will be monitored during the procedure. The primary outcome is to determine the sensitivity, specificity, and optimal cutoff points of FTc and PFVV in predicting intradialytic hypotension. The estimated sample size is 183 participants, with analysis performed using ROC curves and multivariate regression. The protocol complies with ethical standards and aims to develop a simple, non-invasive, real-time tool to improve patient safety and individualized management during hemodialysis.",[475,474,501,477],"Uremia; Chronic",[503,504,505,506,477,507,508,509,510],"Carotid ultrasonography","Corrected flow time","Peak flow velocity variability","Intradialytic hypotension","Ultrasonographic predictors","Vascular ultrasonography","Fluid management","Dialysis safety",{"date":483,"type":42},{"date":513,"type":42},"2025-02-01",{"date":515,"type":21},"2025-08-30",{"name":48,"class":49},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":4},"100594657","phase-2-sintilimab-plus-anlotinib-as-second-or-further-line-therapy-for-es-sclc-who-have-progressed-after-anti-pd-1l1-therapy-100594657","NCT07022301","Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1\u002FL1 Therapy","A Phase II Study Evaluating the Safety and Efficacy of Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti- PD- 1\u002FL1 Therapy","Inclusion Criteria:\n\n* 1\\. At the time of signing the informed consent form, both men and women must be at least 18 years old.\n* 2\\. Widespread recurrent small cell lung cancer diagnosed by histology or cytology and progressing after 3 months of standard immunization.\n* 3\\. According to RECIST 1.1 criteria, patients must have at least one measurable lesion (lesions that have undergone radiotherapy must show clear progression in order to be considered measurable lesions).\n* 4\\. ECOG PS score: 0-1 points.\n* 5\\. Expected survival period ≥ 3 months.\n* 6\\. Important organ functions must meet the following standards:\n\n  1\\) Blood routine examination: (No blood transfusion or use of cytokine drugs such as G-CSF for corrective treatment within 2 weeks before screening)\n  1. Hemoglobin (HB) ≥ 90 g\u002FL;\n  2. Absolute neutrophil count (ANC) ≥ 1.5 × 10\\*9\u002FL;\n  3. Platelet count (PLT) ≥ 90 × 10\\*9\u002FL;\n  4. White blood cell count (WBC) ≥ 3.0 × 109\u002FL and\\\u003C15 × 10\\*9\u002FL; 2) Other tests: (did not receive human serum albumin injection within 14 days before screening)\n  5. AST and ALT ≤ 3 x ULN;\n  6. ALP ≤ 2.5 x ULN (≤ 5 x ULN if there is bone metastasis);\n  7. TBiL≤1x ULN；\n  8. ALB≥30g\u002FL；\n  9. Cr ≤ 1.5 x ULN, while creatinine clearance rate (CrCL) ≥ 60mL\u002Fmin (Cockcroft Gault formula);\n  10. TSH ≤ 1 x ULN (if abnormal, FT3 and FT4 levels should be examined simultaneously. If FT3 and FT4 levels are normal, they can be included in the group)\n  11. APTT ≤ 1.5 x ULN, while INR or PT ≤ 1.5 x ULN (not receiving anticoagulant therapy).\n  12. Male QTc\\\u003C450 ms, female QTc\\\u003C470 ms, LVEF ≥ 50%\n* 7\\. Non surgical sterilization or female patients of childbearing age must undergo a serum pregnancy test within 3 days before the first medication, and the result must be negative; And it must be non lactating. Female patients of childbearing age or male patients with partners of childbearing age must agree to use efficient contraception methods during the study period and within 6 months after the last administration of the study drug.\n* 8\\. The patient voluntarily joined this clinical study and signed an informed consent form, with good compliance and the ability to cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Imaging shows that the tumor has invaded large blood vessels or has unclear boundaries with blood vessels.\n* 2\\. Imaging shows the presence of obvious pulmonary hollow or necrotic tumors.\n* 3\\. Symptomatic central nervous system metastases (such as brain metastases or meningeal metastases).\n* 4\\. Patients with conditions such as malignant meningitis and spinal cord compression.\n* 5\\. Persons who have suffered from other malignant tumors in the past or at the same time, unless they are skin basal cell carcinoma, superficial bladder cancer, skin squamous cell carcinoma, cervical carcinoma in situ or other carcinoma in situ that have achieved complete remission at least 5 years before screening and do not need or are not expected to need other treatment during the study period.\n* 6\\. Those who have had or currently have objective evidence of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, tissue pneumonitis (such as bronchitis, occlusive vasculitis), drug-induced pneumonia, or screening period CT showing active pneumonia or lung function examination confirming severe impairment of lung function.\n* 7\\. Individuals with any active, known or suspected autoimmune diseases (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple sclerosis, vasculitis, glomerulonephritis, uveitis, pituitary inflammation, hyperthyroidism, etc.). Type I diabetes patients who are allowed to receive stabilizing dose insulin treatment, hypothyroidism patients who only need hormone replacement treatment, and skin diseases (such as eczema, vitiligo, or psoriasis) that do not require systemic treatment and have no acute deterioration within 1 year before the screening period.\n* 8\\. Patients suspected of having active pulmonary tuberculosis should undergo chest X-ray, sputum examination, and exclusion based on clinical symptoms and signs. Individuals with a history of active pulmonary tuberculosis infection within the previous year should be excluded, even if they have been treated; Subjects with a history of active pulmonary tuberculosis infection more than one year ago should also be excluded unless it is proven that the previous course and type of anti tuberculosis treatment used were appropriate.\n* 9\\. Clinical symptoms or diseases of the heart that have not been well controlled, such as: (1) NYHA grade 2 or above heart failure, (2) unstable angina, (3) myocardial infarction within 1 year, and (4) clinically significant supraventricular or ventricular arrhythmias that require treatment or intervention.\n* 10\\. Patients with hypertension who cannot achieve good control with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).\n* 11\\. Urine routine showed urinary protein ≥++, and 24-hour urinary protein quantification was confirmed to be\\>1.0 g through quantitative detection of urinary protein.\n* 12\\. For individuals with a tendency towards thrombosis or undergoing thrombolytic\u002Fanticoagulant therapy, prophylactic use of low-dose aspirin (≤ 100mg\u002Fd) and low molecular weight heparin (≤ 40mg\u002Fd) is allowed.\n* 13\\. Those who have received\\>30 Gy of chest radiation therapy within the first 6 months of randomization, and have undergone major surgical treatment within the first 4 weeks of randomization, but have not recovered from the toxicity and\u002For complications of previous intervention measures to NCI-CTC AE ≤ 1 degree (except for hair loss and indicators clearly defined in the inclusion criteria).\n* 14\\. Within the first 6 months of randomization, there have been arterial\u002Fvenous thrombotic events, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism.\n* 15\\. Individuals with a daily cough\u002Fhemoptysis volume greater than 2.5mL within the first month of randomization. Individuals with a history of hereditary or acquired bleeding or coagulation dysfunction. Within the first 3 months of randomization, there have been significant clinical bleeding symptoms or clear bleeding tendencies, such as gastrointestinal bleeding, hemorrhagic gastric ulcers, etc.\n* 16\\. Participants who have experienced severe infections within the previous month prior to randomization, including but not limited to infection complications requiring hospitalization, bacteremia, severe pneumonia, etc; Subjects with any active infection, or experiencing unexplained fever\\>38.5 ℃ during screening or before the first dose.\n* 17\\. Patients who have received anti-tumor vaccines or other immunomodulatory drugs (such as interleukin-2, thymosin, shiitake polysaccharides, etc.) within the previous month of randomization, or patients who will receive attenuated live vaccines.\n* 18\\. Subjects who have received systemic therapy with corticosteroids (\\>10 mg\u002Fday of prednisone or other equivalent hormones) or other immunosuppressive agents within the previous month prior to randomization. In the absence of active autoimmune diseases, inhalation or topical use of corticosteroids, as well as adrenal hormone replacement therapy with a dose ≤ 10 mg\u002Fday of prednisone efficacy dose, are allowed.\n* 19\\. Known to have a positive history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). It is known that there is active hepatitis or co infection with hepatitis B and hepatitis C. (hepatitis B reference: HBsAg is positive, and the HBV DNA detection value exceeds the upper limit of normal value; Hepatitis C reference: HCV antibody positive and HCV virus titer detection value exceeding the upper limit of normal.\n* 20\\. are known to have experienced allergic reactions to other monoclonal antibodies or any component of anlotinib.\n* 21\\. Those who are currently participating in other clinical studies or have been randomized for less than 4 weeks (or 5 half lives of the study drug) since the end of the previous clinical study (last dose);\n* 22\\. According to the researchers' assessment, there are other factors that may affect the research results or lead to the forced termination of this study, such as alcohol abuse, drug use, drug abuse, other serious illnesses (including mental illnesses) that require concurrent treatment, serious laboratory test abnormalities, and family or social factors that may affect medication safety.",{"count":7,"type":21},[450],"The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1\u002FL1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three weeks per cycle. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) , disease control rate (DCR) and safety.",[528,529],"Small Cell Lung Cancer Extensive Stage","Resistance to Immunotherapy","2025-06-12",{"date":532,"type":42},"2025-06-15",{"date":534,"type":21},"2025-07",{"date":536,"type":21},"2029-05",{"name":48,"class":49},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":22,"phases":547,"briefSummary":548,"conditions":549,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":4},"100595078","phase-4-effect-of-henagliflozin-on-renal-outcomes-in-non-dialysis-patients-with-advanced-chronic-kidney-disease--a-multicenter-prospective-randomized-controlled-trialhero--ackd-100595078","NCT07027774","Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD）","A Multicenter, Prospective, Randomized, Controlled Study Evaluating the Progression of Renal Function in Patients With Late-Stage Chronic Kidney Disease Treated With Henagliflozin","Inclusion Criteria:\n\n* The investigator considers that the participant does not require Henagliflozin or any other SGLT-2 inhibitor therapy, nor deems such therapy absolutely inappropriate; and based on local laboratory results within 6 months before the screening visit and at the screening visit, the following criteria must be met:\n\n  1. 10 mL\u002Fmin\u002F1.73m² ≤ eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² (CKD-EPI equation), and\n  2. 150 mg\u002Fg (16.95 mg\u002Fmmol) ≤ Urine Albumin-to-Creatinine Ratio (UACR) \\\u003C 5000 mg\u002Fg (565 mg\u002Fmmol)\n* Age ≥ 18 years, male or femal\n* Participants with 20 mL\u002Fmin\u002F1.73m² ≤ eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² must be on a stable and tolerated dose of an ACE inhibitor (ACEI) or ARB for at least 4 weeks, unless intolerant (reasons for intolerance must be documented). Participants with 10 mL\u002Fmin\u002F1.73m² ≤ eGFR \\\u003C 20 mL\u002Fmin\u002F1.73m² should have ACEI\u002FARB use determined by the investigator based on the patient's clinical status and KDIGO guideline recommendations;\n* Anticipated time to requiring dialysis is greater than 1 month;\n* Provision of written informed consent (illiterate participants may use a thumbprint in lieu of a signature).\n\nExclusion Criteria:\n\n* Received SGLT2 inhibitor treatment within 8 weeks prior to enrollment or with a history of SGLT2 inhibitor intolerance;\n* Receiving combined therapy with an ACE inhibitor (ACEi) and an ARB, or a renin inhibitor combined with ACEi or ARB (based on self-report at screening and randomization visits);\n* On maintenance dialysis, has a functioning kidney transplant, or is a planned living donor transplant recipient (based on self-report at screening and randomization visits);\n* Polycystic kidney disease, active lupus nephritis, or systemic vasculitis;(5) Symptomatic hypotension, or systolic blood pressure \\\u003C90 mmHg or \\>180 mmHg at screening;\n* ALT or AST levels \\>3 times the upper limit of normal (ULN) at screening;\n* Received any intravenous immunosuppressive therapy within the previous 3 months; or any subject who received prednisone \\>45 mg\u002Fday (or equivalent dose) within the previous 3 months;\n* Current use or use within 12 weeks prior to enrollment of glucagon-like peptide-1 (GLP-1) receptor agonist medications (e.g., liraglutide, semaglutide, dulaglutide, etc.) or current participation in another clinical trial of glucose-lowering drugs that may affect kidney or cardiovascular outcomes;(9) Severe malnutrition (serum albumin \\\u003C25 g\u002FL) and\u002For severe anemia (hemoglobin \\\u003C70 g\u002FL);\n* Known poor adherence to clinical follow-up or medication;\n* Myocardial infarction, unstable angina, or stroke within 12 weeks prior to enrollment;\n* Underwent coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass grafting \\[CABG\\]) or valve repair\u002Freplacement within 12 weeks prior to enrollment, or plans to undergo any of these procedures after randomization;(13) Any disease other than kidney or cardiovascular disease (e.g., but not limited to, malignancy) that, in the investigator's clinical judgment, is associated with a life expectancy of less than 2 years;\n* Active malignancy requiring treatment at the time of the first visit (except for successfully treated basal cell carcinoma, treated squamous cell carcinoma, or thyroid cancer);\n* Currently pregnant, breastfeeding, or a woman of childbearing potential (WOCBP) unless using a highly effective method of contraception;\n* Type 1 diabetes;(17) Investigator considers the patient unable to understand and\u002For comply with the study procedures and\u002For follow-up, or any condition that, in the investigator's opinion, may lead to the patient's inability to complete the study.\n* Additionally, subjects will be excluded at the randomization visit if any of the following occur:\n\n  1. Did not adhere to the run-in treatment;\n  2. No longer willing to be randomized and followed for at least 2 years;\n  3. Considered unsuitable for randomization by the local investigator; OR experienced ketoacidosis, heart attack (myocardial infarction), stroke, hospitalization for heart failure, hospitalization for urinary tract infection, or acute kidney injury during the run-in period.",{"count":546,"type":21},429,[395],"This is a multicenter, prospective, randomized, controlled study that will enroll approximately 429 subjects. The screening period will last 4-8 weeks. Subjects will undergo pre-screening based on eGFR and urinary albumin-to-creatinine ratio (UACR). Only non-dialysis subjects meeting the following criteria confirmed by local laboratories within 6 months prior to screening will be eligible for central laboratory screening:\n\n10 mL\u002Fmin\u002F1.73m² ≤ eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² and 150 mg\u002Fg (16.95 mg\u002Fmmol) ≤ UACR \\\u003C 5000 mg\u002Fg (565 mg\u002Fmmol).\n\nUnless contraindicated due to intolerance, subjects with 20 mL\u002Fmin\u002F1.73m² ≤ eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m² must receive stable, maximally tolerated labeled daily doses of ACEi or ARB for at least 4 weeks prior to randomization. For subjects with 10 mL\u002Fmin\u002F1.73m² ≤ eGFR \\\u003C 20 mL\u002Fmin\u002F1.73m², investigators will determine ACEi\u002FARB treatment based on patient condition per KDIGO guidelines. Other antihypertensive, lipid-lowering, and glucose-lowering therapies should be stabilized for approximately 4 weeks before randomization. Investigators are encouraged to maintain stability of medications known to affect serum creatinine levels during screening and approximately 2 weeks prior to any serum chemistry measurements throughout the study. Eligible subjects will be randomized in a 1:1:1 ratio to receive Henagliflozin (10 mg q.d., 5 mg q.d.) or conventional therapy.\n\nThereafter, subjects will undergo laboratory assessments, concomitant medication review, adverse event collection, and clinical endpoint ascertainment at Week 4 (Day 30), Week 12 (Day 90), and Week 24 (Day 180), followed by every 12-week intervals. Throughout the study, all subjects will receive glycemic, blood pressure (target SBP \\\u003C140 mmHg and DBP \\\u003C90 mmHg), and lipid management according to current guidelines. All subjects will complete an end-of-study visit. Subjects discontinuing study drug prematurely should continue all subsequent study visits.",[550],"Chronic Kidney Disease Stage 4","2025-06-11",{"date":553,"type":42},"2025-06-18",{"date":555,"type":21},"2025-07-10",{"date":88,"type":21},{"name":48,"class":49},{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":299,"enrollmentInfo":566,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":567,"conditions":568,"keywords":570,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":580,"leadSponsor":582,"locationsCount":50},"100594699","pleth-variability-index-for-predicting-low-blood-pressure-during-maintenance-hemodialysis-100594699","NCT07022847","Pleth Variability Index for Predicting Low Blood Pressure During Maintenance Hemodialysis","The Value of Pleth Variability Index in Predicting Hypotension During Maintenance Hemodialysis: A Prospective Observational Multicenter Study","PVI-HD","Inclusion Criteria:\n\n* Adults aged 18 to 80 years.\n* Diagnosis of end-stage renal disease and undergoing maintenance hemodialysis for more than 3 months.\n* Able and willing to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Severe cardiac arrhythmias or significant peripheral vascular disease that may interfere with PVI measurements.\n* Local edema, skin lesions, or other conditions that prevent accurate PVI monitoring.\n* History of hemodynamic instability unrelated to dialysis.\n* Pregnant or breastfeeding women.\n* Known allergy or contraindication to materials used in the hemodialysis circuit.\n* Unable to cooperate with study procedures.\n* Participation in another interventional clinical study within the past 30 days.",{"count":448,"type":21},"What is this study about? We are studying whether the Pleth Variability Index (PVI)-a simple, non-invasive measurement from a pulse oximeter-can help predict low blood pressure (hypotension) during routine maintenance hemodialysis. Low blood pressure during dialysis is a common and potentially serious complication. Our goal is to find out if monitoring PVI can help identify patients at risk, so that early action can be taken.\n\nWho can join? Adults aged 18 to 80 years. Patients who have been receiving maintenance hemodialysis regularly for more than 3 months.\n\nThose who are willing and able to participate and sign an informed consent form.\n\nWho cannot join? Patients with severe heart rhythm problems, severe peripheral circulation problems, or swelling that makes PVI measurement unreliable.\n\nPatients who are pregnant or breastfeeding. Patients allergic to the dialysis filter or unable to cooperate with the study procedures.\n\nWhat will happen during the study? PVI Measurement: Your PVI will be checked with a simple fingertip device before starting dialysis and again 30 minutes after dialysis begins.\n\nBlood Pressure Monitoring: Your blood pressure will be closely watched throughout the dialysis session.\n\nData Collection: Information about your age, medical history, medications, lab results, dialysis settings, and other standard measurements will be recorded.\n\nWhat are the benefits and risks? Benefits: By identifying patients at higher risk for low blood pressure during dialysis, the study may lead to safer and more comfortable dialysis treatment in the future.\n\nRisks: All measurements used in this study are safe and non-invasive, with no extra risk compared to routine care.\n\nYour Rights and Safety Participation is completely voluntary-you may leave the study at any time without affecting your medical care.\n\nThe study has been reviewed and approved by the hospital's ethics committee. Your privacy and personal data will be strictly protected.",[569,477,474,475],"Hypotension and Shock",[571,477,475,572,573,574,575,576],"Pleth Variability Index","Blood Pressure Monitoring","End-Stage Renal Disease","Non-invasive Monitoring","Predictive Marker","Maintenance Dialysis","2025-06-07",{"date":532,"type":42},{"date":513,"type":42},{"date":581,"type":21},"2025-06-30",{"name":48,"class":49},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":599,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":608,"leadSponsor":610,"locationsCount":4},"100593368","ultrasound-guided-microbubble-removal-and-filter-lifespan-during-crrt-a-pilot-crossover-study-100593368","NCT07005531","Ultrasound-Guided Microbubble Removal and Filter Lifespan During CRRT: A Pilot Crossover Study","Impact of Ultrasound-Guided Microbubble Clearance During CRRT Circuit Priming on Filter Lifespan: A Randomized Crossover Pilot Trial","Inclusion Criteria:\n\n* Age ≥18 years, regardless of sex;\n* Admission to the intensive care unit (ICU) with a diagnosis of acute kidney injury (AKI) or chronic kidney disease (CKD) requiring continuous renal replacement therapy (CRRT);\n* Expected to receive at least two sessions of CRRT;\n* Written informed consent obtained from the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n* Presence of severe coagulopathy (such as disseminated intravascular coagulation, DIC) or platelet count \\\u003C30×10\\^9\u002FL;\n* Contraindications to anticoagulation therapy;\n* Change in APACHE II score \\>5 points, or changes in coagulation parameters and platelet count exceeding 20% between the two treatment sessions;\n* Any other condition deemed unsuitable for participation by the investigators.",{"count":247,"type":21},[24],"What is this study about? This study is designed to evaluate whether ultrasound-guided removal of microbubbles during circuit priming in Continuous Renal Replacement Therapy (CRRT) can extend the filter lifespan for critically ill patients who require CRRT. The investigators aim to determine if this technique improves the duration of effective filter use and reduces complications related to filter clotting.\n\nWho can join? Adults (18 years or older) admitted to the Intensive Care Unit (ICU) and diagnosed with acute kidney injury (AKI) or chronic kidney failure (CKD) who require CRRT and are expected to undergo at least two sessions of CRRT treatment.\n\nParticipants or their legal representatives must provide signed informed consent.\n\nWho cannot join? Patients with severe coagulation disorders, platelet count \\\u003C30×10\\^9\u002FL, contraindications to anticoagulation, significant changes in clinical scores or blood tests between CRRT sessions, or any other condition deemed unsuitable by the investigator.\n\nWhat will happen during the study?\n\nTwo Treatment Methods:\n\nConventional Priming (Control): The CRRT circuit will be primed following the standard visual bubble inspection protocol.\n\nUltrasound-Guided Priming (Intervention): The circuit will be primed using real-time ultrasound to detect and remove microbubbles from key locations.\n\nEach participant will receive both interventions in random order, separated by a washout period of at least 24 hours.\n\nSafe and Routine Monitoring:\n\nUltrasound scans will be performed on the filter and circuit to guide microbubble removal.\n\nStandardized CRRT treatment protocols, including filter type and anticoagulation regimen, will be used for all sessions.\n\nOther Data Collection:\n\nPatient information (e.g., age, sex, medical history, APACHE II score) CRRT treatment details (e.g., filter lifespan, filter clotting incidence, coagulation parameters) Monitoring of adverse events and clinical outcomes (including 28-day survival and treatment costs) What are the benefits and risks? Benefits: This study may provide evidence for a simple, non-invasive method to reduce filter clotting, improve CRRT efficiency, and enhance patient outcomes.\n\nRisks: Ultrasound monitoring is non-invasive and does not add risk beyond standard care. All procedures are standard clinical practice.\n\nYour Rights and Safety Voluntary Participation: Participation is voluntary; withdrawal is allowed at any time without affecting clinical care.\n\nEthical Approval: The study protocol is reviewed and approved by the hospital's ethics committee.\n\nConfidentiality: All personal information and test results will be kept confidential.",[594,595,596,597,598],"Acute Kidney Injury","Continuous Renal Replacement Therapy (CRRT)","Filter Clotting","Microbubbles","Ultrasound-Guided Microbubble Removal",[595,600,597,601,596,602,180,603],"Filter Lifespan","Ultrasound Guidance","Circuit Priming","Randomized Crossover Trial","2025-06-03",{"date":606,"type":42},"2025-06-05",{"date":581,"type":21},{"date":609,"type":21},"2026-06-29",{"name":48,"class":49},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":620,"conditions":621,"keywords":623,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":634},"100590136","cerebral-large-vessel-occlusion-stroke-multiomics-biosample-cohort-100590136","NCT06963489","Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort","CLOMB","Inclusion Criteria:\n\n1. Age over 18 years.\n2. Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography.\n3. Availability of complete clinical and follow-up information required for the study.\n4. Availability of blood and\u002For thrombus biological samples.\n5. Voluntary written informed consent signed by the patient or their family (1) For retrospectively enrolled patients, a \"broad informed consent\" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the informed consent.\n\n(2) For prospectively enrolled patients, informed consent for this study was signed at the time of enrollment by the patient or their family.\n\nExclusion Criteria:\n\n1. Patients for whom biological samples cannot be obtained;\n2. Patients or their family members who refuse to sign the informed consent form.",{"count":619,"type":21},500,"This multicenter, ambispective cohort study establishes a comprehensive multiomics biobank from five stroke centers, encompassing thrombi, intracranial blood, peripheral arterial\u002Fvenous blood, and clinical-laboratory-imaging-follow-up data from patients with acute ischemic stroke with large vessel occlusion (AIS-LVO).",[622,351],"Large Vessel Occlusion",[624,625],"multiomics","acute ischemic stroke with large vessel occlusion","2025-05-09",{"date":628,"type":42},"2025-05-11",{"date":630,"type":42},"2025-04-27",{"date":632,"type":21},"2028-02-29",{"name":48,"class":49},5,{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":22,"phases":644,"briefSummary":645,"conditions":646,"keywords":4,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":657,"locationsCount":50},"100580903","trial-of-rescue-endovascular-treatment-for-progressive-acute-mild-ischemic-stroke-with-basilar-artery-occlusion-with-extended-time-window-100580903","NCT06843356","Trial of Rescue Endovascular Treatment for Progressive Acute Mild Ischemic Stroke With Basilar Artery Occlusion With Extended Time Window","RESCUE-BAO","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Symptoms and signs consistent with basilar artery ischemia.\n3. Basilar artery or vertebral artery occlusion confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA); if vertebral artery occlusion is present, it should completely block blood flow along the basilar artery.\n4. First-time onset meeting the criteria for mild ischemic stroke diagnosis: NIHSS score \\\u003C6.\n5. Symptom progression within 7 days of the first onset.\n6. Symptom progression: NIHSS score increase ≥4 points or consciousness level increase ≥2 points from the initial NIHSS score.\n7. Time from symptom onset to randomization \\>24 hours.\n8. Symptom progression to randomization time ≤24 hours.\n9. NIHSS score ≥10 before randomization.\n10. pc-ASPECTS before randomization ≥ 6\n11. The patient or their family members are willing to comply with the protocol requirements and data collection procedures, understand, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Symptom progression due to intracranial hemorrhage, brain edema, or other clear causes (including but not limited to infarct hemorrhagic transformation, new infarction in non-occluded vascular regions, severe infection, high fever, heart or kidney dysfunction, hypovolemia, or severe electrolyte disturbances).\n2. mRS \\>2.\n3. Factors in the target vessel that are expected to prevent completion of endovascular treatment.\n4. Multiple vessel occlusions.\n5. Prior imaging confirmed or investigator-assessed chronic basilar artery occlusion.\n6. Presence of untreated intracranial aneurysms, intracranial tumors (except small meningiomas), or intracranial vascular malformations.\n7. Intracranial hemorrhage within the past 6 months, including parenchymal brain hemorrhage, intraventricular hemorrhage, or subarachnoid hemorrhage.\n8. Gastrointestinal or urinary tract bleeding, acute myocardial infarction, cranial trauma, or major surgery within the past month.\n9. Presence of active bleeding, coagulation disorders, or uncorrectable bleeding tendencies.\n10. Platelet count \\\u003C40×10\\^9\u002FL, or INR \\>2 during anticoagulation therapy (irreversible).\n11. Severe heart, liver, or kidney dysfunction or other severe systemic late-stage diseases.\n12. Known allergy to iodine contrast agents or other treatment-related drugs.\n13. Medically uncontrolled refractory hypertension (defined as persistent systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg) (Note: Participants can be included if their blood pressure is controllable with medication and maintained at an acceptable level).\n14. Uncontrollable blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL.\n15. Pregnancy or breastfeeding.\n16. Life expectancy \\\u003C6 months.\n17. Participation in other clinical studies that may affect outcome assessment.\n18. Investigator's judgment that the patient is unsuitable for participation in this study or may face significant risks (e.g., due to mental illness, cognitive, or emotional disorders preventing understanding and\u002For compliance with study procedures and\u002For follow-up).",{"count":643,"type":21},159,[24],"A prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial to evaluate whether best medical management (BMM) combined with endovascular therapy (EVT) improves neurological outcomes compared to BMM alone in patients with progressive acute mild ischemic stroke due to basilar artery occlusion within an extended time window.",[647,648,649,650],"Acute Mild Ischemic Stroke","Basilar Artery Occlusion","Rescue Endovascular Treatment","Extended Time Window","2025-04-13",{"date":653,"type":42},"2025-04-15",{"date":655,"type":42},"2024-06-01",{"date":262,"type":21},{"name":48,"class":49},""]